FR3061659B1 - Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou de l'epicatechine et/ou du methylhydroxychalcone polymere et/ou d - Google Patents

Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou de l'epicatechine et/ou du methylhydroxychalcone polymere et/ou d Download PDF

Info

Publication number
FR3061659B1
FR3061659B1 FR1771175A FR1771175A FR3061659B1 FR 3061659 B1 FR3061659 B1 FR 3061659B1 FR 1771175 A FR1771175 A FR 1771175A FR 1771175 A FR1771175 A FR 1771175A FR 3061659 B1 FR3061659 B1 FR 3061659B1
Authority
FR
France
Prior art keywords
limoneme
lupeol
epicatechin
cinnamaldehyde
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1771175A
Other languages
English (en)
Other versions
FR3061659A1 (fr
Inventor
Guy Faustin Monkam Nitcheu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US16/481,853 priority Critical patent/US20200268770A1/en
Priority to PCT/IB2017/057731 priority patent/WO2018127748A1/fr
Priority to CN201780082728.5A priority patent/CN110139643A/zh
Priority to EP17825613.7A priority patent/EP3565536A1/fr
Publication of FR3061659A1 publication Critical patent/FR3061659A1/fr
Application granted granted Critical
Publication of FR3061659B1 publication Critical patent/FR3061659B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Dispositif pour briser les pointes d’une ampoule contenant un liquide. L’invention concerne un dispositif permettant de briser sans risque de blessures les pointes d’une ampoule contenant un liquide pour permettre l’écoulement de ce liquide. Il est constitué d’un boîtier (1) présentant un orifice (2) dans lequel est introduite la pointe de l’ampoule (3). Un levier (4) est articulé en (6) sur le boîtier (1) et pourvu d’une saillie (5). Lorsque l’utilisateur exerce sur le levier (4) une force antagoniste à celle du ressort (7), la saillie (5) appuie sur la pointe de l’ampoule (3) pour la briser et la faire tomber dans le boîtier (1). Le dispositif selon l’invention est particulièrement destiné à l’ouverture des ampoules pharmaceutiques. Figure pour l’abrégé : Fig. 1
FR1771175A 2017-01-07 2017-11-07 Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou de l'epicatechine et/ou du methylhydroxychalcone polymere et/ou d Active FR3061659B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/481,853 US20200268770A1 (en) 2017-01-07 2017-12-07 Pharmaceutical composition used for treating metabolic syndrome disorders, infectious diseases, and complications thereof
PCT/IB2017/057731 WO2018127748A1 (fr) 2017-01-07 2017-12-07 Composition pharmaceutique utilisée pour traiter les troubles du syndrome métabolique, les maladies infectieuses, et leurs complications.
CN201780082728.5A CN110139643A (zh) 2017-01-07 2017-12-07 一种用于治疗代谢紊乱综合征、炎症及其并发症的药物成分
EP17825613.7A EP3565536A1 (fr) 2017-01-07 2017-12-07 Composition pharmaceutique utilisée pour traiter les troubles du syndrome métabolique, les maladies infectieuses, et leurs complications.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1770014 2017-01-07
FR1770014A FR3061658A1 (fr) 2017-01-07 2017-01-07 Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou du methylhydroxychalcone polymere et/ou du beta-sitosterol et/ou de

Publications (2)

Publication Number Publication Date
FR3061659A1 FR3061659A1 (fr) 2018-07-13
FR3061659B1 true FR3061659B1 (fr) 2020-02-21

Family

ID=58632521

Family Applications (2)

Application Number Title Priority Date Filing Date
FR1770014A Withdrawn FR3061658A1 (fr) 2017-01-07 2017-01-07 Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou du methylhydroxychalcone polymere et/ou du beta-sitosterol et/ou de
FR1771175A Active FR3061659B1 (fr) 2017-01-07 2017-11-07 Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou de l'epicatechine et/ou du methylhydroxychalcone polymere et/ou d

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR1770014A Withdrawn FR3061658A1 (fr) 2017-01-07 2017-01-07 Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou du methylhydroxychalcone polymere et/ou du beta-sitosterol et/ou de

Country Status (5)

Country Link
US (1) US20200268770A1 (fr)
EP (1) EP3565536A1 (fr)
CN (1) CN110139643A (fr)
FR (2) FR3061658A1 (fr)
WO (1) WO2018127748A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3061658A1 (fr) * 2017-01-07 2018-07-13 Guy Faustin Monkam Nitcheu Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou du methylhydroxychalcone polymere et/ou du beta-sitosterol et/ou de
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
FR3100128B1 (fr) * 2019-08-30 2022-02-18 Nitcheu Guy Faustin Monkam Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications
CN111000849A (zh) * 2019-12-19 2020-04-14 淮阴师范学院 羽扇豆醇dyc-6的应用和产品
CN111840262A (zh) * 2020-07-15 2020-10-30 广东工业大学 肉桂醛衍生物在制备预防和/或治疗新型冠状病毒感染药物中的应用
FR3121038B1 (fr) * 2021-03-27 2024-06-14 Nitcheu Guy Faustin Monkam Composition pharmaceutique destinée à inhiber l’infectiosité des virus à bicouche lipidique, à traiter les maladies associées et leurs complications.
CN113648421A (zh) * 2021-08-19 2021-11-16 中山大学中山眼科中心 磺酰脲类药物在制备治疗葡萄膜炎的药物中的应用
GB202113028D0 (en) * 2021-09-13 2021-10-27 Ucl Business Ltd Sterol therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967030B2 (en) * 2003-01-14 2005-11-22 Wright Jonathan V Formulation for insulin and glucose control
US20070196520A1 (en) * 2004-03-01 2007-08-23 Fhg Corporation D/B/A Nutraceuticals Methods and materials for reducing or eliminating risk factors associated with syndrome x
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
CN101028363A (zh) * 2006-02-28 2007-09-05 舒刚 植物或草药及其挥发油提取物在制备治疗糖尿病药物中的新用途
CA2595096A1 (fr) * 2007-07-27 2009-01-27 Innovative Life Sciences Corporation Produit a base d'herbes medicinales comprenant de la cannelle et du chocolat
FR3061658A1 (fr) * 2017-01-07 2018-07-13 Guy Faustin Monkam Nitcheu Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou du methylhydroxychalcone polymere et/ou du beta-sitosterol et/ou de

Also Published As

Publication number Publication date
US20200268770A1 (en) 2020-08-27
FR3061659A1 (fr) 2018-07-13
WO2018127748A1 (fr) 2018-07-12
FR3061658A1 (fr) 2018-07-13
EP3565536A1 (fr) 2019-11-13
CN110139643A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
FR3061659B1 (fr) Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou de l'epicatechine et/ou du methylhydroxychalcone polymere et/ou d
BRPI0607027A2 (pt) dispositivo de injeção
TWI544939B (zh) 人因手操作流體分配裝置
CY1113086T1 (el) Μια συσκευη διανομης υγρου
AR058491A1 (es) Dispositivo
FR2988015B1 (fr) Dispositif de distribution de liquide muni d'un capuchon amovible
BR112013033092A2 (pt) dispositivo para fornecimento melhorado de líquidos voláteis
BRPI0514797A (pt) dispositivo de liberação de fluido
EP1839752A3 (fr) Extrémité de pipette
BRPI0414025A (pt) dispositivo de distribuição, recipiente de distribuição e conta-gotas dotados com o mesmo
EP3075405A3 (fr) Dispositif de sortie
MA32832B1 (fr) Cartouche, distributeur de medicament pour doses de medicament solides et utilisatons de cette cartouche et de ce distributeur de medicament
UY30101A1 (es) Una ampolla utilizable como una jeringa y una unidad de jeringa que comprende la ampolla
WO2017018076A1 (fr) Unité d'aiguille
ATE451181T1 (de) Vorrichtung zur abgabe flüchtiger flüssigkeitströpfchen
EP1742685A1 (fr) Pousse-seringue
FR3048344B1 (fr) Contenant pour produit cosmetique liquide
EA200870363A1 (ru) Аппликаторы для интравагинальных лекарственных средств
EA200700229A1 (ru) Аппликатор для текучих веществ для медицинского и/или косметического применения
US20170295893A1 (en) Fashionable piece of jewelry that provides aromatherapy
BRPI0416521A (pt) dispositivo de dispensação
ES2175749T3 (es) Dispositivo para almacenar y extraer a presion compuestos fluidos.
EP2366506A3 (fr) Dispositif de préhension pour le conditionnement de fournitures
FR3082731B1 (fr) Dispersions comprenant des gouttes macroscopiques dispersees dans une phase continue comprenant des particules reflechissantes
FR2912936B1 (fr) Dispositif de pulverisation d'une composition de brillance

Legal Events

Date Code Title Description
PLSC Publication of the preliminary search report

Effective date: 20181207

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7